Precision BioSciences, Inc. (DTIL) NASDAQ

4.97

-0.1(-1.97%)

Updated at September 08 04:00PM

Currency In USD

Precision BioSciences, Inc.

Address

302 East Pettigrew Street

Durham, NC 27701

United States of America

Phone

919 314 5512

Sector

Healthcare

Industry

Biotechnology

Employees

108

First IPO Date

March 28, 2019

Key Executives

NameTitlePayYear Born
Mr. Michael AmorosoPresident, Chief Executive Officer & Director1.09M1978
Mr. Naresh TannaChief of Staff to Chief Executive Officer & Head of Investor Relations0N/A
Mr. Dario Scimeca J.D.General Counsel & Secretary576,4321976
Dr. Jefferson J. Smith Ph.D.Co-Founder & Chief Research Officer640,1951973
Mr. John Alexander Kelly R.Ph.Chief Financial Officer & Principal Accounting Officer671,3821967
Dr. Murray Abramson M.D., M.P.H.Senior Vice President & Head of Clinical Development0N/A
Dr. Cassie Gorsuch Ph.D.Chief Scientific Officer0N/A
Ms. Juli BlancheChief People Officer0N/A
Ms. Cindy AtwellChief Development & Business Officer0N/A
Mr. Neil Leatherbury M.S.Senior Vice President and Head of Chemistry, Manufacturing & Controls0N/A

Description

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.